scispace - formally typeset
L

Leslie Cope

Researcher at Johns Hopkins University School of Medicine

Publications -  202
Citations -  65516

Leslie Cope is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: DNA methylation & Cancer. The author has an hindex of 63, co-authored 181 publications receiving 54177 citations. Previous affiliations of Leslie Cope include University Medical Center Groningen & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Roger E. McLendon, +233 more
- 23 Oct 2008 - 
TL;DR: The interim integrative analysis of DNA copy number, gene expression and DNA methylation aberrations in 206 glioblastomas reveals a link between MGMT promoter methylation and a hypermutator phenotype consequent to mismatch repair deficiency in treated gliobeasts, demonstrating that it can rapidly expand knowledge of the molecular basis of cancer.

Integrated genomic analyses of ovarian carcinoma

Daphne W. Bell, +261 more
TL;DR: The Cancer Genome Atlas project has analyzed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours as mentioned in this paper.
Journal ArticleDOI

Summaries of Affymetrix GeneChip probe level data

TL;DR: It is found that the performance of the current version of the default expression measure provided by Affymetrix Microarray Suite can be significantly improved by the use of probe level summaries derived from empirically motivated statistical models.
Journal ArticleDOI

affy---analysis of Affymetrix GeneChip data at the probe level

TL;DR: The affy package is an R package of functions and classes for the analysis of oligonucleotide arrays manufactured by Affymetrix that provides the user with extreme flexibility when carrying out an analysis and make it possible to access and manipulate probe intensity data.
Journal ArticleDOI

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

TL;DR: Evaluating the efficacy of PD-1 blockade in patients with advanced mismatch repair–deficient cancers across 12 different tumor types showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor–1 (PD-1).